Why Intuitive Surgical Stock Plunged Today
Intuitive Surgical (ISRG) shares fell about 14% after the company reported Q2 adjusted EPS of $2.80 and revenue of $2.89B, both above Wall Street estimates, but kept its full-year da Vinci procedure growth forecast at 13.5% to 15.5%. Investors cited the unchanged outlook as disappointing. The stock hit its lowest level since early 2024.
How this was made
The 30-second read
Why it matters
Guidance reiteration without a raise appears to have outweighed the earnings beat, triggering a large single-day decline and multiple compression concerns.
Market read
Traders should focus on how investors interpret unchanged procedure-growth guidance after a Q2 beat, since that is the catalyst for the move.
What to watch
The article points to specific volume headwinds (ACA enrollment, China competition) that may be cyclical or policy-driven, so the market may be extrapolating them too aggressively into the full year.
Background
ISRG reported Q2 adjusted EPS of $2.80 on revenue of $2.89B, but left full-year da Vinci procedure growth guidance unchanged at roughly 13.5% to 15.5%.
Ticker impact
ISRG shares plunged about 14% after it kept its full-year da Vinci procedure growth forecast unchanged despite Q2 beating estimates.
Near-term downside pressure likely persists as investors reprice the probability of slower da Vinci procedure growth versus prior expectations.
The article cites unchanged full-year procedure growth guidance (13.5% to 15.5%) and notes the stock hit the lowest level since early 2024 after the guidance failed to support a beat-and-raise narrative.
Market effects
Highlights sensitivity of surgical-robotics and premium medtech valuations to procedure-growth guidance versus earnings beats.
Mentions headwinds including rising competition in China, which can weigh on regional growth expectations for medtech peers.
Reinforces global investor focus on procedure volumes and reimbursement/coverage dynamics (e.g., ACA enrollment) for medtech demand.
Counterpoint
The quarter beat was strong, and management expects growth to land near the midpoint, which could still support a stabilization trade if investors were overly focused on the lack of an upgrade.
Key entities
- public_companyIntuitive Surgical
Robotic surgical tools maker whose da Vinci procedure-growth outlook was reiterated, driving the selloff.
- analyst_firmWilliam Blair
Maintains an outperform rating but cited headwinds including China competition and declining procedure volumes tied to ACA enrollment.
%252FIntuitive%252520Surgical%252520Inc%252520location%252520sign-by%252520Sundry%252520Photography%252520via%252520iStock.jpg&w=3840&q=75)